Immunotherapy of lymphoma: Update and review of the literature

Current Opinion in Oncology

Volumn 15, Issue 5, 2003, Pages 363-370

  Berdeja, Jesús G ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Lymphoma; Monoclonal antibodies; Vaccines

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; EPRATUZUMAB; HU 1D10; IBRITUMOMAB TIUXETAN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB; TUMOR VACCINE; UNCLASSIFIED DRUG; YTTRIUM 90;

BINDING SITE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG BINDING; HUMAN; IMMUNOTHERAPY; LYMPHOMA; MEDICAL LITERATURE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOTHERAPY; LYMPHOMA; RADIOIMMUNOTHERAPY;

EID: 0041330442     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200309000-00003     Document Type: Review

References (98)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al.: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Jones RJ, Ambinder RF, Piantadosi S, et al.: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991, 77:649-653.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
4. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000, 18:3135-3143.
5. Coiffier B, Haioun C, Ketterer N, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
6. Milpied N, Vasseur B, Parquet N, et al.: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000, 11 (Suppl 1):113-116.
7. Treon SP, Kelliher A, Keele B, et al.: Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. Semin Oncol 2003, 30:248-252.
8. Horwitz SM, Tsai D, Twist C: Rituximab is effective therapy for post-transplant lymphoproliferative disorder not responding to reduction in immunosuppression: a prospective trial in adults and children. Proc Am Soc Clin Oncol 2001, 20:284a.
9. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptabre toxicity. J Clin Oncol 2001, 19:2153-2164.
10. O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
11. Buckstein R, Imrie K, Spaner D, et al.: Autologous stem cell transplants combined with rituximab for rerapsed follicular lymphoma achieve prolonged clinical and molecular remissions. Blood 2001, 98:680a.
12. Flinn IW, Jones RJ, Goodrich A, et al.: Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays. Blood 2001, 98:676a.
13. Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999, 10:655-661.
14. Hainsworth JD, Litchy S, Barton JH, et al.: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003, 21:1746-1751.
15. Leonard JP, Link BK: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 2002, 29:81-86.
16. Gingrich RD, Dahle CE, Hoskins KF, et al.: Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 1990, 75:2375-2387.
17. Link B, Kahl B, Czuczman M, et al.: A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. Blood 2001, 98:606a.
18. Loffler A, Kufer P, Lutterbuse R, et al.: A recombinant bispecific singre-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
19. Bohlen H, Manzke O, Patel B, et al.: Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993, 53:4310-4314.
20. Haagen IA, de Lau WB, Bast BJ, et al.: Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 1994, 39:391-396.
21. Bohlen H, Hopff T, Manzke O, et al.: Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993, 82:1803-1812.
22. Dreier T, Baeuerle PA, Fichtner I, et al.: T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003, 170:4397-4402.
23. Daniel PT, Kroidl A, Kopp J, et al.: Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 1998, 92:4750-4757.
24. Cochlovius B, Kipriyanov SM, Stassar MJ, et al.: Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J Immunol 2000, 165:888-895.
25. Cochlovius B, Kipriyanov SM, Stassar MJ, et al.: Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000, 60:4336-4341.
26. De Gast GC, Van Houten AA, Haagen IA, et al.: Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995, 4:433-437.
27. Anderson PM, Crist W, Hasz D, et al.: G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992, 80:2826-2834.
28. Mack M, Riethmuller G, Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 1995, 92:7021-7025.
29. Loffler A, Gruen M, Wuchter C, et al.: Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003, 17:900-909.
30. Clynes RA, Towers TL, Presta LG, et al.: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [see comments]. Nat Med 2000, 6:443-446.
31. Isaacs JD, Greenwood J, Waldmann H: Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol 1998, 161:3862-3869.
32. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
33. Golay J, Zaffaroni L, Vaccari T, et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-3908.
34. Flieger D, Renoth S, Beier I, et al.: Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000, 204:55-63.
35. Hofmeister JK, Cooney D, Coggeshall KM: Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3- dependent apoptosis. Blood Cells Mol Dis 2000, 26:133-143.
36. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
37. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186.
38. Ghetie MA, Bright H, Vitetta ES: Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001, 97:1392-1398.
39. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276.
40. Czuczman M, Grillo-Lopez A, White CA, et al.: Progression free survival after six years follow up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. Blood 2001, 98:601a.
41. Czuczman M, Fallen A, Mohr A, et al.: Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report. Blood 2001, 98:601a.
42. Sacchi S, Tucci A, Merli F, et al.: Phase II study with fludarabine and cyclophosphamide plus rituximab in relapsed follicular lymphoma patients. Blood 2002, 100:572a.
43. Gregory SA, Venugopal P, Adler S, et al.: Combined fludarabine, mitoxantrone, and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin's lymphoma. Blood 2002, 100:362a.
44. Vitolo U, Boccomini C, Ladetto M, et al.: High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with brief chemo-immunotherapy FND+rituximab. Blood 2002, 100:359a.
45. Zinzani PL: Group ICS: A multicenter randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Blood 2002, 100:93a.
46. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001, 19:389-397.
47. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242. Phase III randomized trial showing a survival advantage with the combination of CHOP-rituximab versus CHOP. Likely will change standard of care of DLC lymphoma.
48. Caligiuri MA, Murray C, Robertson MJ, et al.: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993, 91:123-132.
49. Meropol NJ, Porter M, Blumenson LE, et al.: Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 1996, 2:669-677.
50. Fehniger TA, Cooper MA, Nuovo GJ, et al.: CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
51. Friedberg JW, Neuberg D, Gribben JG, et al.: Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002, 117:828-834.
52. Wilson S, Hurst D, Yuen A, et al.: IL-2 mediated NK cell expansion correlates with clinical response to rituximab: results of two phase I trials of the combination of IL-2 and rituximab. Blood 2001, 98:602a.
53. Berdeja JG, Hess A, Ambinder RF, et al.: Lymphokine activated killer cells augment rituximab antibody dependent cellular cytotoxicity in patients with rituximab refractory lymphoma. Blood 2002, 100:576a.
54. Stern AS, Podlaski FJ, Hulmes JD, et al.: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 1990, 87:6808-6812.
55. Kobayashi M, Fitz L, Ryan M, et al.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845.
56. Banks RE, Patel PM, Selby PJ: Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995, 71:655-659.
57. Ansell SM, Witzig TE, Kurtin PJ, et al.: Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002, 99:67-74.
58. Gidlund M, Orn A, Wigzell H, et al.: Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978, 273:759-761.
59. Herberman RR, Ortaldo JR, Bonnard GD: Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 1979, 277:221-223.
60. Herberman RB: Effect of alpha-interferons on immune function. Semin Oncol 1997, 24:S978-S980.
61. Sivaraman S, Venugopal P, Huang X, et al.: Effects of in vitro exposure to interferon alpha on CD20 expression in chronic lymphocytic leukemia cells. Ann Oncol 1999, 10.
62. Davis TA, Maloney DG, Grillo-Lopez AJ, et al.: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000, 6:2644-2652.
63. Sacchi S, Federico M, Vitolo U, et al.: Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001, 86:951-958.
64. Ozer H, Wiernik PH, Giles F, et al.: Recombinant interferon-alpha therapy in patients with follicular lymphoma. Cancer 1998, 82:1821-1830.
65. VanderMolen LA, Steis RG, Duffey PL, et al.: Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst 1990, 82:235-238.
66. Hagenbeek A, Carde P, Meerwaldt JH, et al.: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998, 16:41-47.
67. Grillo-Lopez A, Dallaire B, Shen C, et al.: Treatment options for patients with relapsed low-grade or follicular lymphoma: the role of IDEC-C2B8. Antibody Immunoconjugates Radiopharmaceuticals 1995, 8:60.
68. Kaminski MS, Fig LM, Zasadny KR, et al.: Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992, 10:1696-1711.
69. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
70. Kaminski MS, Estes J, Zasadny KR, et al.: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000, 96:1259-1266.
71. Vose JM, Wahl RL, Saleh M, et al.: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000, 18:1316-1323.
72. Horning SJ, Lucas JB, Younes A: Iodine-131 tositumomab for non-Hodgkin's lymphoma patients who progressed after treatment with rituximab: results of a multicenter phase II study. Blood 2000, 96:508a.
73. Kaminski M, Zelenetz AD, Leonard J, et al.: Bexxar radioimmunotherapy produces a substantial number of durable complete responses in patients with multiply relapsed or refractory low grade or transformed low grade non-Hodgkin's lymphoma. Blood 2002, 100:356a.
74. Kaminski M, Tuck M, Regan D, et al.: High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab. Blood 2002, 100:356a.
75. Witzig TE, White CA, Wiseman GA, et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3793-3803.
76. Wiseman GA, White CA, Stabin M, et al.: Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000, 27:766-777.
77. Wiseman GA, Gordon LI, Multani PS, et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002, 99:4336-4342.
78. Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463. First reported randomized trial comparing two immunotherapies: rituximab versus radioimmunotherapy.
79. Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3262-3269.
80. Witzig TE, White CA, Gordon LI, et al.: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003, 21:1263-1270. Pooled data of five studies with Y-90 ibritumomab tiuxetan reporting the short-term and long-term safety of radioimmunotherapy.
81. Bennet JM, Zelenetz AD, Press OW, et al.: Incidence of myelodysplastic syndromes and acute myelogenous leukemia in patients with low-grade non-Hodgkin's lymphoma treated with Bexxar. Blood 2001, 98:335a.
82. Czuczman M, Witzig T, Gaston I, et al.: Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome or acute myelogenous leukemia. Blood 2002, 100:357a.
83. Gopal AK, Gooley TA, Maloney DG, et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: a multi-variable cohort analysis. Blood 2003. The first published experience replacing high-dose radioimmunotherapy for conventional high-dose TBI or chemo-based myeloablative regimens for high-dose therapy and autologous stem cell transplantation. The treatment is safe and feasible with results seemingly equal if not better with the radioimmunoconjugates.
84. Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158-3162.
85. Press OW, Unger JM, Braziel RM, et al.: A Phase II Trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group protocol S9911. Blood 2003. This study outlines some of the important developments in immunotherapy, including combination therapy and moving immunotherapy earlier in the course of disease.
86. Kwak LW, Campbell MJ, Czerwinski DK, et al.: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209-1215.
87. Simons JW, Jaffee EM, Weber CE, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Rest 1997, 57:1537-1546.
88. Kato K, Cantwell MJ, Sharma S, et al.: Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1996, 101:1133-1141.
89. Hsu FJ, Caspar CB, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997, 89:3129-3135.
90. Timmerman JM, Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999, 50:507-529.
91. Timmerman JM, Czerwinski DK, Davis TA, et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.
92. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
93. Timmerman JM, Levy R: Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000, 164:4797-4803.
94. Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171-1177.
95. Osterroth F, Garbe A, Fisch P, et al.: Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000, 95:1342-1349.
96. McCormick AA, Kumagai MH, Hanley K, et al.: Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A 1999, 96:703-708.
97. Timmerman JM, Singh G, Hermanson G, et al.: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002, 62:5845-5852.
98. Timmerman J, Czerwinsk DK, Taidi B: A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma. Blood 2000, 96:578a.